Sarepta Therapeutics, Inc. (NASDAQ:SRPT) registered a -6.03% decrease, still its new closing price is 262.12% up from the company’s 1 year high of 63.73.It posted -7.77% losses in previous 5 sessions and is now the subject of 5 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 6 buy or better ratings. The 18 stock analysts following this company have an average price target at $62.94, with individual PT in the $32.00-$102.00 range. The shares moved at $28.97, implying that brokerage firms see shares gaining about 143.86% in twelve months time.
Sarepta Therapeutics, Inc. (SRPT) SEC Form 4 News
The stock is getting much attention these days as insiders are offloading shares while they posted a 5.61% rise year to date. A Senior Vice President, CFO at Sarepta Therapeutics, Inc. (SRPT) offloaded shares in a transaction closed on Monday October 17, 2016. Mahatme Sandesh sold 30,000 shares in the company at $50.08 each and collected $1,502,000 in proceeds. Mahatme Sandesh now owns 31,532 shares in the company after this transaction. A SVP, Regulatory Affairs & Qual in the company, Ruff Shamim, disclosed a transaction on Thursday September 22, 2016 that ended up generating $438,001 from the sale of 7,311 shares at $60 per share.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Upcoming Results on Tap
Sarepta Therapeutics, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.70 in that period. Sales during the quarter are predicted to arrive at $15.83 million.
Earnings surprise history: Last quarter, the company posted approximately $0 in revenue and EPS of $-1.18. The mean forecast was for $1.06 million and $-1.32 a share, respectively. One quarter earlier, revenue for the stock was at $0, with earnings at $-1.35/share.
Sarepta Therapeutics, Inc. (SRPT) Brokerage Update
Sarepta Therapeutics, Inc. (SRPT) is in RBC Capital Mkts’s research list so their analyst rating change is noteworthy. These shares were upgraded to Outperform from Sector Perform by RBC Capital Mkts, according to news reported on Monday September 19, 2016.Another important research note was issued by Jefferies on Monday September 19, 2016.The firm upgraded SRPT to Hold from Underperform. Over the last six months and over the last three months, the shares of Sarepta Therapeutics, Inc. (SRPT), have changed 14.60% and -29.01%, respectively.
